MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy